Robert L. Coleman

Active 1994–2026

Also published as
Robert L Coleman
257
Papers
44,230
Citations
107
h-index
248
i10-index

Citations

Citations per year for Robert L. Coleman1974: 1 citations1994: 2 citations1996: 3 citations1997: 4 citations1998: 10 citations1999: 9 citations2000: 11 citations2001: 15 citations2002: 15 citations2003: 31 citations2004: 29 citations2005: 33 citations2006: 50 citations2007: 77 citations2008: 156 citations2009: 162 citations2010: 205 citations2011: 267 citations2012: 267 citations2013: 238 citations2014: 318 citations2015: 274 citations2016: 340 citations2017: 398 citations2018: 367 citations2019: 1,505 citations2020: 1,933 citations2021: 1,782 citations2022: 1,721 citations2023: 1,453 citations2024: 2,344 citations2025: 1,087 citations2026: 23 citations1975–1993: no citations, so these years are not shown1995: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,383 citing papers, 23.4% of this breakdownChina: 2,311 citing papers, 12.4% of this breakdownItaly: 1,203 citing papers, 6.4% of this breakdownUnited Kingdom: 1,154 citing papers, 6.2% of this breakdownGermany: 777 citing papers, 4.2% of this breakdownCanada: 744 citing papers, 4% of this breakdownFrance: 730 citing papers, 3.9% of this breakdownSpain: 606 citing papers, 3.2% of this breakdownJapan: 532 citing papers, 2.8% of this breakdownAustralia: 521 citing papers, 2.8% of this breakdownNetherlands: 404 citing papers, 2.2% of this breakdownSouth Korea: 401 citing papers, 2.1% of this breakdown
0%23.4%Other 26.4%

Fields

  • Medicine61.9%
  • Biochemistry, Genetics and Molecular Biology29.6%
  • Immunology and Microbiology2.5%
  • Materials Science1.1%
  • Neuroscience1.1%
  • Engineering1%
  • Other2.8%

Topics

  • Ovarian cancer diagnosis and treatment7.4%
  • PARP inhibition in cancer therapy5.6%
  • Endometrial and Cervical Cancer Treatments4.7%
  • MicroRNA in disease regulation2%
  • Breast Cancer Treatment Studies2%
  • HER2/EGFR in Cancer Research2%
  • Other76.3%

Coauthors

All papers

Open in search
  1. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Powell - New England Journal of Medicine 2023 cited by 800

  2. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

    Authors: , , , , , , - Cancer Treatment Reviews 2020 cited by 1,136

  3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian and 17 more - The Lancet 2017 cited by 1,704

  4. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 372

  5. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

    Authors: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 1,869

  6. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz and 10 more - The Lancet Oncology 2017 cited by 1,133

  7. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit - Journal of Clinical Oncology 2022 cited by 384

  8. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2006 cited by 1,296

  9. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 cited by 394

  10. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carol Aghajanian, Michael A. Bookman - New England Journal of Medicine 2019 cited by 929

  11. Exploring and comparing adverse events between PARP inhibitors

    Authors: , , , - The Lancet Oncology 2019 cited by 479

  12. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Iain A. McNeish - The Lancet Oncology 2016 cited by 1,200

  13. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 cited by 432

  14. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2022 cited by 222

  15. openalex_id:w4226022025

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , cited by 180

  16. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 cited by 602

  17. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 483

  18. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 cited by 673

  19. The forefront of ovarian cancer therapy: update on PARP inhibitors

    Authors: , , , , , , - Annals of Oncology 2020 cited by 370

  20. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin Lin, Clare L. Scott - Cancer Discovery 2017 cited by 417

  21. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - International Journal of Gynecological Cancer 2021 cited by 230

  22. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish - Nature Communications 2021 cited by 205

  23. RNA interference in the clinic: challenges and future directions

    Authors: , , , , - Nature reviews. Cancer 2010 cited by 814

  24. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 153